Literature DB >> 21278384

Compromised myocardial energetics in hypertrophied mouse hearts diminish the beneficial effect of overexpressing SERCA2a.

Ilka Pinz1, Rong Tian, Darrell Belke, Eric Swanson, Wolfgang Dillmann, Joanne S Ingwall.   

Abstract

The sarcoplasmic reticulum calcium ATPase (SERCA) plays a central role in regulating intracellular Ca(2+) homeostasis and myocardial contractility. Several studies show that improving Ca(2+) handling in hypertrophied rodent hearts by increasing SERCA activity results in enhanced contractile function. This suggests that SERCA is a potential target for gene therapy in cardiac hypertrophy and failure. However, it raises the issue of increased energy cost resulting from a higher ATPase activity. In this study, we determined whether SERCA overexpression alters the energy cost of increasing myocardial contraction in mouse hearts with pressure-overload hypertrophy using (31)P NMR spectroscopy. We isolated and perfused mouse hearts from wild-type (WT) and transgenic (TG) mice overexpressing the cardiac isoform of SERCA (SERCA2a) 8 weeks after ascending aortic constriction (left ventricular hypertrophy (LVH)) or sham operation. We found that overexpressing SERCA2a enhances myocardial contraction and relaxation in normal mouse hearts during inotropic stimulation with isoproterenol. Energy consumption was proportionate to the increase in contractile function. Thus, increasing SERCA2a expression in the normal heart allows an enhanced inotropic response with no compromise in energy supply and demand. However, this advantage was not sustained in LVH hearts in which the energetic status was compromised. Although the overexpression of SERCA2a prevented the down-regulation of SERCA protein in LVH hearts, TG-LVH hearts showed no increase in inotropic response when compared with WT-LVH hearts. Our results suggest that energy supply may be a limiting factor for the benefit of SERCA overexpression in hypertrophied hearts. Thus, strategies combining energetic support with increasing SERCA activity may improve the therapeutic effectiveness for heart failure.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21278384      PMCID: PMC3060468          DOI: 10.1074/jbc.M110.210757

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure.

Authors:  M I Miyamoto; F del Monte; U Schmidt; T S DiSalvo; Z B Kang; T Matsui; J L Guerrero; J K Gwathmey; A Rosenzweig; R J Hajjar
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

Review 2.  Ca channels in cardiac myocytes: structure and function in Ca influx and intracellular Ca release.

Authors:  D M Bers; E Perez-Reyes
Journal:  Cardiovasc Res       Date:  1999-05       Impact factor: 10.787

3.  Transgenic expression of sarcoplasmic reticulum Ca(2+) atpase modifies the transition from hypertrophy to early heart failure.

Authors:  K Ito; X Yan; X Feng; W J Manning; W H Dillmann; B H Lorell
Journal:  Circ Res       Date:  2001-08-31       Impact factor: 17.367

Review 4.  Manipulating cardiac contractility in heart failure: data from mice and men.

Authors:  Gerald W Dorn; Jeffery D Molkentin
Journal:  Circulation       Date:  2004-01-20       Impact factor: 29.690

Review 5.  Is depressed myocyte contractility centrally involved in heart failure?

Authors:  Steven R Houser; Kenneth B Margulies
Journal:  Circ Res       Date:  2003-03-07       Impact factor: 17.367

6.  Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure.

Authors:  F del Monte; E Williams; D Lebeche; U Schmidt; A Rosenzweig; J K Gwathmey; E D Lewandowski; R J Hajjar
Journal:  Circulation       Date:  2001-09-18       Impact factor: 29.690

7.  Contractile reserve and intracellular calcium regulation in mouse myocytes from normal and hypertrophied failing hearts.

Authors:  K Ito; X Yan; M Tajima; Z Su; W H Barry; B H Lorell
Journal:  Circ Res       Date:  2000-09-29       Impact factor: 17.367

8.  Decreased energetics in murine hearts bearing the R92Q mutation in cardiac troponin T.

Authors:  Maryam M Javadpour; Jil C Tardiff; Ilka Pinz; Joanne S Ingwall
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

9.  Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling.

Authors:  Federica del Monte; Djamel Lebeche; J Luis Guerrero; Tsuyoshi Tsuji; Angelia A Doye; Judith K Gwathmey; Roger J Hajjar
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-25       Impact factor: 11.205

10.  Transgenic rat hearts overexpressing SERCA2a show improved contractility under baseline conditions and pressure overload.

Authors:  Oliver J Müller; Mathias Lange; Henning Rattunde; Hans-Peter Lorenzen; Matthias Müller; Norbert Frey; Cordula Bittner; Warner Simonides; Hugo A Katus; Wolfgang M Franz
Journal:  Cardiovasc Res       Date:  2003-08-01       Impact factor: 10.787

View more
  16 in total

Review 1.  A network-oriented perspective on cardiac calcium signaling.

Authors:  Christopher H George; Dimitris Parthimos; Nicole C Silvester
Journal:  Am J Physiol Cell Physiol       Date:  2012-07-25       Impact factor: 4.249

2.  Dexamethasone promotes hypertrophy of H9C2 cardiomyocytes through calcineurin B pathway, independent of NFAT activation.

Authors:  K N Sangeetha; B S Lakshmi; S Niranjali Devaraj
Journal:  Mol Cell Biochem       Date:  2015-10-29       Impact factor: 3.396

Review 3.  Calcium mishandling in diastolic dysfunction: mechanisms and potential therapies.

Authors:  Michelle L Asp; Joshua J Martindale; Frazer I Heinis; Wang Wang; Joseph M Metzger
Journal:  Biochim Biophys Acta       Date:  2012-09-27

4.  Acetylation of SERCA2a, Another Target for Heart Failure Treatment?

Authors:  Xiongwen Chen; Xiaoying Zhang; Scott Gross; Steven R Houser; Jonathan Soboloff
Journal:  Circ Res       Date:  2019-04-26       Impact factor: 17.367

5.  Tropomyosin dephosphorylation results in compensated cardiac hypertrophy.

Authors:  Emily M Schulz; Richard N Correll; Hajer N Sheikh; Marco S Lofrano-Alves; Patti L Engel; Gilbert Newman; Jo El J Schultz; Jeffery D Molkentin; Beata M Wolska; R John Solaro; David F Wieczorek
Journal:  J Biol Chem       Date:  2012-11-12       Impact factor: 5.157

Review 6.  Tropomyosin de-phosphorylation in the heart: what are the consequences?

Authors:  Emily M Schulz; David F Wieczorek
Journal:  J Muscle Res Cell Motil       Date:  2013-06-22       Impact factor: 2.698

7.  CD36 protein influences myocardial Ca2+ homeostasis and phospholipid metabolism: conduction anomalies in CD36-deficient mice during fasting.

Authors:  Terri A Pietka; Matthew S Sulkin; Ondrej Kuda; Wei Wang; Dequan Zhou; Kathryn A Yamada; Kui Yang; Xiong Su; Richard W Gross; Jeanne M Nerbonne; Igor R Efimov; Nada A Abumrad
Journal:  J Biol Chem       Date:  2012-09-27       Impact factor: 5.157

8.  Energetic Dysfunction Is Mediated by Mitochondrial Reactive Oxygen Species and Precedes Structural Remodeling in Metabolic Heart Disease.

Authors:  Ivan Luptak; Fuzhong Qin; Aaron L Sverdlov; David R Pimentel; Marcello Panagia; Dominique Croteau; Deborah A Siwik; Markus M Bachschmid; Huamei He; James A Balschi; Wilson S Colucci
Journal:  Antioxid Redox Signal       Date:  2019-06-25       Impact factor: 8.401

Review 9.  Matrix revisited: mechanisms linking energy substrate metabolism to the function of the heart.

Authors:  Andrew N Carley; Heinrich Taegtmeyer; E Douglas Lewandowski
Journal:  Circ Res       Date:  2014-02-14       Impact factor: 17.367

10.  Metabolomic analysis of two different models of delayed preconditioning.

Authors:  Claudio Bravo; Raymond K Kudej; Chujun Yuan; Seonghun Yoon; Hui Ge; Ji Yeon Park; Bin Tian; William C Stanley; Stephen F Vatner; Dorothy E Vatner; Lin Yan
Journal:  J Mol Cell Cardiol       Date:  2012-11-02       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.